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Abstract   
The microbiome also known as “The forgotten organ” embraces the collective genome of all 
bacteria, archaea, fungi, protists, and viruses found in the host body surfaces and cavities. It is 
acknowledged that the microbiota has a role in many physiological functions such as the regulation 
of inflammation, immune response or haematopoiesis among others. The involvement of dysbiosis 
(alteration of the homeostatic microbiota) in the development of many pathologies like depression 
or cancer is a current topic of interest. On the other hand, carcinogenesis results as an accumulation 
of genetic and epigenetic alterations which are favoured by risk factors such as lifestyle, diet or 
dysbiosis. The latter has recently been discovered to either contribute or prevent carcinogenesis by 
modulating tumour or host cell microenvironment, respectively. Moreover, the microbiota has been 
found to influence chemotherapy, radiotherapy and immunotherapy efficacy and toxicity. 
Therefore, in this dissertation it is discussed the role of the microbiota as the cause, consequence 
or both of carcinogenesis as well as the mechanisms and the bacterial species that are involved in 
the efficacy or toxicity of certain anticancer drugs. It is relevant because it opens new strategies to 
prevent cancer or to enhance therapeutic agents against cancer which could result in positive 
clinical outcomes for cancer patients. One new strategy is the oncomicrobiotics, a select “cocktail 
of bacteria and/or bacterial products” as an adjunctive therapy to cancer with the intention of 
improving the immune response through optimizing the gut microbiota.  
Resum 
La microbiota també coneguda com “l’òrgan oblidat” és el conjunt de bacteris, arqueus, fongs, 
protists i virus que es troben a les superfícies corporals de l’hoste. Se sap que la microbiota 
desenvolupa un paper en moltes funcions fisiològiques com la regulació de la inflamació, la resposta 
immunològica o l’hematopoesi entre d’altres. La implicació de la disbiosi (l’alteració de la microbiota 
homeostàtica) en el desenvolupament de patologies com la depressió o el càncer és un tema actual 
d’interès. D’altra banda, la carcinogènesi és la conseqüència d’acumulacions d’alteracions 
genètiques i epigenètiques que es veuen potenciades per certs factors de risc tals com l’estil de vida, 
la dieta o la disbiosi. Recentment, aquesta última, s’ha vist que contribueix o pot prevenir la 
carcinogènesi modulant el microambient tumoral o el de les cèl·lules hoste respectivament. A més, 
s’ha vist que la microbiota influeix en l’eficàcia i la toxicitat de la quimioteràpia, la immunoteràpia i 
la radioteràpia. Així doncs, en aquest treball es discuteix el paper de la microbiota com a causa, 
conseqüència o ambdues de la carcinogènesi així com els mecanismes i les espècies bacterianes 
involucrades en l’eficàcia o toxicitat de certs medicaments anti-cancerígens. Aquesta discussió és 
rellevant ja que obre noves portes a estratègies, per prevenir el càncer o millorar els agents 
terapèutics contra el càncer, que podrien esdevenir en resultats clínics positius pels pacients 
oncològics. Un exemple d’això seria l’ús dels oncomicrobiòtics un “còctel de bacteris i/o productes 
bacterians”  com a teràpia addicional al càncer, per a la millora de la resposta immunitària a través 
de l’optimització de la microbiota intestinal.  
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Integration of the different fields included in the thesis 
The main field of this dissertation is microbiology since it revolves around the microbiota 
and its influence on cancer initiation and it spotlights the oncomicrobiotics, a new 
therapeutic field based on microbiota modulation and/or its products in order to prevent 
cancer or improve its treatment. Secondary fields such as immunology and pharmacology 
and therapeutics are equally important to fully understand and develop a comprehensive 
view of this work. On the one hand, the immune system has a crucial role in carcinogenesis 
and in shaping the microbiota, and, at the same time, it is affected by cancer and 
microorganisms. On the other hand, efficacy and toxicity of certain anticancer drugs depend 
on the gut microbiota state. Therefore, the immune system, the microbiota and cancer are 
three concepts that are interconnected in a bidirectional manner and they cannot be seen 
separately (Figure 1). 
For all the reasons stated before, microbiology, immunology and pharmacology and 
therapeutics are integrated in this thesis.  
 
 
Figure 1. How the microbiota, the immune system and cancer are interconnected. DAMP, danger-associated molecular 







1.1. What is carcinogenesis? 
Carcinogenesis is the production or development of cancer through genotypic, phenotypic 
and epigenetic changes which upset the normal balance between cell proliferation and cell 
death. Most cancers arise from random somatic alterations in key genes of cell proliferation, 
survival and growth. These genetic changes are importantly favoured by a number of risk 
factors such as lifestyle, diet and inflammation, and the environment where tumours evolve 
provides a unique source of signalling cues that affects cancer cell growth, survival, 
movement and metastasis (2).  
Carcinogenesis appears as a result of accumulations of genetic alterations including 
activation of oncogenes or deregulation of tumour suppressor genes and DNA repair 
systems.  
Proto-oncogenes are physiologic regulators of cell proliferation and differentiation that can 
become oncogenes when suffering from a mutation. The latter encodes oncoproteins which 
have the ability of skipping the cell cycle strict regulation and thus, cell growth control is 
lost. Examples of oncoproteins frequently mutated in cancer are growth factors (epithelial, 
vascular…), growth factor receptors, signal transduction proteins, nuclear regulatory 
protein and cell-cycle regulators.   
Tumour suppressor genes on the other hand encode proteins that are related with the 
inhibition of cell proliferation or growth signalling pathways, and with the liberation of 
proteins that promote apoptosis and DNA repair systems. Tumour suppressor genes loss 
their function in cancer cell whereas oncogenes are more expressed (3). 
Carcinogenesis is a process that consist of several steps that could be sum up with 
proliferation cell (tumour), malignant transformation (cancer), local invasion (neighbouring 
tissues) and metastasis (invasion of distant sites of the body through blood stream/ 
lymphatic vessels), being the last step the more dangerous and lethal form of carcinogenesis 
because at that point cancer have the ability to spread all around the body and control of 
the disease becomes extremely difficult (3).  
1.2. The human microbiota 
It might be thought that microorganisms only involve infections, when in fact they do not 
only have a parasitic relationship with human beings but also a mutualistic and commensal 
one. This statement is endorsed by two different theories that are believed to explain 
eukaryotic cells inception. One of them is Lynn Margulis’ theory of endosymbiosis which 
holds that the organelles distinguishing eukaryote cells such as mitochondria and 
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chloroplasts were acquired through intracellular symbiosis with bacteria. The other one, 
which is gathering strength and is also backed by Lynn Margulis holds that the first 
eukaryotic cell was formed as a result of the symbiosis between bacteria and archaea (4). 
So, the human microbiota is the ecological community of microorganisms – from bacteria 
to archaea, fungi, protozoa or viruses–  that reside the epithelial barrier surfaces of our 
body which are exposed to the external environment (gastrointestinal and respiratory tract, 
vagina, skin, etc.) and exhibits mainly commensalism and mutualism with its host. It is 
acquired after birth through vertical transmission and shaped throughout life by 
environmental exposure. The term microbiome, which is usually confused with microbiota, 
refers to the collective genome of those microorganisms. In order to put into perspective 
the relevance of this symbiotic relationship with microorganisms, it is worth knowing that 
commensal microorganisms (which are normally present on body surfaces covered by 
epithelial cells) are at least equally numerous as human cells (approximately 3.0·1013) 
although some studies claim that are three times or even ten times higher than human cells. 
Moreover, the number of microbial genes is around 100 times higher than that of the 
human genes although many proteins and metabolites are shared (4, 5). Therefore, the 
symbiosis between human being and microorganisms is acknowledged. On the one hand, 
the intestine offers an ideal microenvironment for microbes to reside, e.g. nutrient rich, 
warm, with adjusted pH and protected. On the other hand, humans greatly benefit from 
microbiota present at the epithelial barrier (particularly in the gut) because they are 
involved in several physiological processes such as host immunity modulation –which 
modulate cancer initiation, progression and response to anticancer–, bone marrow 
haematopoiesis promotion or maturation, local and systemic metabolic functions and 
inflammation. In addition to that, microbiota in contact with intestinal cell regulates 
mucosal immune homeostasis, prevents infestation by occupying ecological niches that 
could be otherwise colonised by pathogen microorganisms, digest complex carbohydrates 
(dietary fibre), lipids and proteins, synthesizes vitamins like vitamin K and controls the 
overpopulation of pathobionts (described as resident microbes with pathogenic 
potential)(6, 7).  
It is in the gut where most of the human microbiota is located forming a dynamic and 
complex ecosystem. Its distribution, diversity, species composition and metabolic outputs 
set the balance of benefit and harm for the host. The intestinal microbiota is shaped by 
constant peristalsis, which move fractions of microbes from low pH environment (stomach) 
to a higher ones (colon), and by antagonistic relationship between species such as 
competition of resources, secretion of antibiotic toxins by some bacteria, or infection chains 
between bacteriophages, bacteria and eukaryotes (8). Depending on how this work, there 
are two different microbial states. On the one hand, eubiosis is the natural equilibrium 
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between the microbiota and the host in order to maintain homeostasis. It is achieved by 
continuous crosstalk between the gut microbiota, immune cells and the mucosal barrier 
that happens mainly in the gut (7). On the other hand, dysbiosis is an alteration of the 
composition, distribution and/or diversity of the microbiota and is statistically associated 
with a pathology and contributes to the aetiology, diagnosis or treatment of the disease. A 
reference population for eubiosis or dysbiosis state is difficult to determine since there is 
an unquestionable variability between healthy individuals attributed to geography, age, 
gender.or.dietary.habits.(9).  
Conversely, it has to be understood that eubiosis is not always a positive term as well as 
dysbiosis is not always a negative one (Figure 2). Some authors have used the expression 
“beneficial dysbiosis” to refer that sometimes an alteration of the microbiota can result in 
benefit of the host while others have stated that “eubiotic gut microbiota may limit the 
unwarranted side effects of various antineoplastic agents” (6).  
 
Figure 2. Detrimental and beneficial effects of dysbiosis in disease outcome. MAMP, microbe-associated  
molecular pattern (6). 
Dysbiosis that can be featured by the bloom of pathobionts, the loss of commensal 
(microbial killing or diminished proliferation) and the loss of diversity. Likewise, it can be 
caused by infection, inflammation, diet and xenobiotics, genetics, familial transmission and 
other factors such as circadian disruption (9).  
As it will be explained in this thesis as a major field of study, dysbiosis has a role in 
carcinogenesis and in the efficacy and toxicity of some cancer therapies. That makes 
commensal microbiota manipulation as one of the most promising therapeutic tools as an 




The main objective of this dissertation is to explain the relationship status between the 
microbiota and carcinogenesis as well as the oncomicrobiotics. In order to do so, more 
concrete aims, listed below, will be achieved:  
- To discuss to what extend carcinogenesis is influenced by microbiota. 
- To discern microbiota alteration in cancer setting and in anticancer therapies 
setting. 
- To explain the influence of the microbiota in host immune response.  
- To explain the influence of the microbiota in the efficacy and toxicity of 
anticancerogenic drugs. 
- To outline the therapeutic benefits of bacteria in cancer setting. 
3. Material and methods 
In order to conduct this bibliographical research, I have widely search for the most trust-
worthy and up-to date articles, reviews and books. To achieve that, I mainly used PubMed® 
a free resource developed by the National Centre for Biotechnology information (NCBI) 
which provided free access to National Library of Medicine’s®(NLM) databases like Medline. 
Medline has citations and abstracts from different fields including medicine and preclinical 
science and each bibliographical reference has a Medical Subject Hiding (MeSH) which allow 
to search articles not only through keywords but also through subjects.  
After carefully choose the most relevant articles to me, I conducted a review of the subject 
previously planned. It starts with a global vision of how carcinogenesis, the human 
microbiota and immune system are interconnected as well as an explanation of basic 
concepts in microbiology and immunology. It follows a gathering of different situations that 
are used to exemplify what is intended to be explained. Finally, it ends with possible 
scenarios in the therapeutic field that this subject might lead, and leaves open the option 
of hypothetical solutions to an efficient anticancer treatment.  
All the articles that I used in this dissertation are referenced with Mendeley®. Thereby, most 
of the information compiled correspond to an article that can be found in the bibliography.  
7 
 
4. Results and discussion 
4.1. The influence of the microbiota in the carcinogenesis. 
The role of bacteria in carcinogenesis is complex, as both pro- and anticarcinogenic 
functions have been attributed to microorganisms. On the one hand, the microbiota has 
positive outcomes in fighting cancer located at distant sites from the gut, due to its ability 
to modulate local and systemic metabolism, inflammation and immunity (10).  On the other 
hand, microbiota can induce carcinogenesis through different pathways. For example, by 
direct oncogenic effects of microorganisms or their products or by alterations in 
carcinogenic metabolites that are microbiota-mediated or by producing trophic factors, 
such as growth factors or by inducing proinflammatory and immunosuppressive effects that 
undermine anticancer immunosurveillance. In addition to that, broad-spectrum antibiotic 
treatment, pathogen exposure, fasting, long-lasting changes in diet and other factors, such 
as cold stress or perturbations of diurnal rhythms, can alter microbiome steadiness and 
thus, can develop carcinogenesis (8).  
There are many studies that support the idea that microbiome and carcinogenesis are not 
isolated concepts.  
To begin with, there is evidence that suggests increased cancer risk with the use of 
antibiotics which links the idea of dysbiosis may cause carcinogenesis. The first clinical 
evidence was published in 2008 by the National Public Health Institute in Finland. A 
nationwide cohort study that included 3,112,624 individuals, aged 30–79 years, with no 
history of cancer was conducted. Antibiotic data used from 1995 to 1997 was collected and 
later, for the next 6 years (1998-2004) those individuals were followed up in order to detect 
if they developed any kind of cancer to finally estimate a relative risk of cancer. Antibiotic 
use was associated with an increased risk of cancer despite having little knowledge of the 
importance of microbiota in carcinogenesis. However, the study pointed out that antibiotic 
use should be considered as an indicator rather than a cause of cancer because there are 
many other factors that can contribute to carcinogenesis and limitations in this study were 
recognised (11).  
Moreover, it has been tested in mouse that pro-carcinogenic phenotypes (induced colitis or 
colon carcinogenesis) expressed by genetically mutated mice (in genes which produce, 
process, or respond to IL-18 that mediate mucosal protective mechanisms) can be 
transferred into wild-type mice by microbiota transfer (7).   
Lastly, resistance or susceptibility to carcinogenesis can be noticed in different studies in 
germ-free mice. This nonsense fact can be explained by the dual role that microbiota may 
play in carcinogenesis. While it is true that it participates in epithelial cell damage, genetic 
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instability and mutation by secreting reactive oxygen and nitrogen species and by 
downregulating DNA repair genes; it is also true that it is required to repair epithelial 
damage in mucosal tissues (7).  
Those examples clearly associate microbiota with carcinogenesis, even though there is a 
lack of insight into the mechanisms by which they happen. One mechanism, though, could 
be inflammation, that on the one hand, creates a carcinogenic environment resulting from 
bacteria and host cells that trigger carcinogenesis and, on the other hand, it is used as a 
communication channel between microbiota and cancer (Figure 3) (2). This communication 
channel occurs through peptides in a quorum sensing fashion and it is thought to contribute 
to metastasis (12).  
Because of microbiota-carcinogenesis association has been made, new therapeutics 
interventions such as microbiota manipulation have been thought. Testing antibiotics, 
probiotics, prebiotics, etc. in preclinical models has just started (13).  
 
Figure 3. The role of inflammation and the microbiota in carcinogenesis. Inflammation,  
known as a hallmark of cancer is influenced in many different ways by the microbiota (4). 
4.2. Immunology and cancer 
Similar to the relationship between the microbiota and carcinogenesis, immunology plays 
a dual role in cancer. On the one hand, it is responsible of immunosurveillance, processes 
by which cells of the immune system look for and recognise foreign pathogens such as 
cancerous cells. On the other hand, inflammation –which is mediated by the immune 
system– is present in almost all the steps of carcinogenesis from initiation and propagation 
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to metastasis, being chronic inflammation highly related with cancer risk. Plus, the 
inflammatory microenvironment developed by tumours, that lead to immunosuppression 
and thus, tumour progression, is also supported by the immune system (14).  
4.2.1. The basis of onco-immunology.   
In an optimal immune situation, the immune system has enough efficacy and specificity to 
eliminate cancer cells. What come next is the description of a seven-step cyclic-process that 
sums up the way the human body generates anticancer immune response to lead to 
effective killing of cancer cells (Figure 4).  
Figure 4. The cancer-immunity cycle (15). 
Cancer cell death –caused by cytotoxic CD8 T cells, natural killers (NK) or chemotherapy 
among others– releases cancer antigens that can be captured by antigen-presenting cells 
(APC) being dendritic cells (DC) the most efficient ones to induce antigen-specific T cell 
response (step 1). Later, antigens are processed by DCs and displayed in major 
histocompatibility I and II (MHC I or II). (MHC I is a cell surface protein that is expressed in all cells 
to display own cell antigens in order to develop self-tolerance. MHC II cell surface protein is only 
present in APCs to display rare or foreign antigens in order to activate antigen-specific T 
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lymphocytes). At this moment DCs have matured and they move to the lymph nodes where 
they present the antigen to naïve CD4+ /CD8+ T cells (steps 2 - 3). Naïve CD8+ T cells then 
become cytotoxic T lymphocytes (CTL) (which eliminate cancer cells ) while naïve CD4+ T 
cells, depending on the different pattern of signals, become helper T cells (Th) (with 
different profiles that generally helps CTLs) or regulatory T cell (Treg) (which contribute to 
immune suppression and diminish CTLs activity). It is a critical step that determines the 
outcome of the immune response towards cancer. If the number of Treg cells outweighs 
the number of Th cells it will be difficult for the immune system to undermine the tumour. 
Finally, effector T cells (primed and activated T cells) traffic to tumour through blood vessels 
(step 4) and infiltrate the tumour bed through endothelial cells (step 5). Eventually, cancer 
cells are recognised by the receptor of effector T cells (TCR) that bind to cancer cells MHC I 
that display the antigen previously presented (step 6) and kill their target by secreting 
cytotoxic mediators such as granzymes A and B and perforin (step 7). This fact provokes the 
release of tumour-associated antigens that not only closes the cancer-immunity cycle but 
also enlarges the immune response (15, 16).   
However, in cancer pathogenesis this cycle does not work as it should because tumours can 
develop mechanisms to scape immunity. There are three major immune escape 
mechanisms. The first one is the loss of antigenicity which is produced by a decrease or 
mutation in MHC I molecules. Therefore, cancer cells can no longer display the cancer-cell 
antigen and CTL lose their target. The result is less specific T cell and less T cell killing. The 
second mechanism is regarding the loss of immunogenicity or immunosuppression. 
Tumours are surrounded by what is called tumour microenvironment (TME) which is a 
complex and dynamic setting developed by themselves that consist of immune cells, cancer 
cells and their bordering stroma (Figure 5). They communicate with each other by immune 
mediator such as cytokines and chemokines that normally modulates immune cells towards 
an immunosuppressive and pro-inflammatory fashion. For example, in the TME the 
extracellular matrix of cancer cell forms a physical barrier to T cell that do not allow them 
to migrate, or there are many cytokines related to angiogenesis and epithelial proliferation. 
The third mechanism related to the capability of cancer cells to become resistant. There 
are different ways they can achieve that, mostly involving genetic alteration. For example, 
they develop intrinsic resistance to local cell death programs such as apoptosis, upregulate 







Figure 5. Different functions of cells subtypes found in TME (17). 
4.2.2.  Immunotherapy 
The recent breakthroughs in the immunobiology field and the understanding of the cancer-
immunity cycle has opened a new field of therapeutic against cancer: immunotherapy.  
Immunotherapy (IT) comes as one of the latest and more promising therapies against 
cancer that might play an important role in polytherapy (18). 
The concept of immunotherapy is vast and includes all kind of immune system –other’s or 
our own– used in order to combat cancer. Cancer immunology is challenging because it is 
difficult to create an immune response to a tissue that is originated in our own body. In 
order to outpace the mechanisms that tumours develop to evade the immune system, the 
aim of IT is to “wake up”, initiate, enhance, harness or boost the immune system and  kill 
cancer cells but not do much as to damage normal cells and generate an unrestrained 
autoimmune response (15).  
Immunotherapy can be classified into two major groups: Active immunotherapy which 
induces an immune response within the body (in vivo) and passive immunotherapy in which 
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the immune response initiated outside the body (ex-vivo) and then is transferred into the 
body.   
Active IT is also divided into three types. The first one is adjuvants, a non-specific therapy 
that acts on the innate immune system. It matures DCs so they move to the lymph node 
and prime T cells. An example of an adjuvant is Bacillus Calmette-Guerin (BCG), a vaccine 
used to prevent tuberculosis but also effective to treat some non-invasive bladder cancer. 
The second one is therapeutic vaccines, a specific therapy that give an exact target in order 
to begin the immune response. An example of this is the peptide vaccine that contains an 
antigen and an adjuvant that when injected in the tumour stimulates DCs. Another example 
is DC therapy (Provenge – spiuleucel-T) used in some prostate cancer. The idea here is to 
vaccinate mature DCs so they can move straight to the lymph nodes and do the antigen-
presentation (19). The third one is immune checkpoint inhibitors one of the most promising 
therapeutics against cancer. The checkpoint pathways have an important role in down 
regulating the immune system. During T-cell activation, T-cells begin to express 
“checkpoints” such as cytotoxic-T-lymphocyte-associated protein 4 (CTLA-4) and 
programmed-cell-death protein 1 (PD-1) to guard against autoimmunity and to protect 
tissues from damage by an over-exuberant immune response to an infection. They are both 
immune-modulating molecules. On the one hand, CTLA-4 regulates the amplitude of the 
initial immune response, the T cell activation. In order to present the peptide to T-cell, not 
only DCs needs MHCII – T-cell receptor (TCR) interaction but also the CD80 – CD28 co-
stimulation. CTLA-4 counteracts CD28 T-cell activation resulting in a decreased T-cell 
activation at initial stages of immune response, typically in the lymph nodes. Plus, CTLA-4 
enhances the proliferation and activation of regulatory T-cells. On the other hand, PD-1 
pathways regulate previously activated T-cells at a later stage of immune response, typically 
in the peripheral tissues. PD-1 receptor expressed in T-cells have affinity to PD-1 ligands 
(PD-1L) which are upregulated in all cells when the immune response begins to stop 
cytotoxic activity of CTL and ensure the immune system does not damage healthy cells. 
Unfortunately, cancer cells take advantage of this natural inhibitory mechanisms by 
expressing inhibitory ligands for these checkpoints (PD-L1 for PD-1 and B7 for CTLA-4) and 
thus, cancer cells become resistant to the immune system. Anti-CTLA-4 and anti-PD1 
therapy through monoclonal antibodies have achieved outstanding results but only in some 
patients. Understanding why there are different responding to these treatments is an object 
of study of this dissertation and it will be discussed later. 
Passive IT which is mainly through T-cell therapy is subdivided into two categories. The first 
one is adoptive T-cell therapy and consist of isolating tumour infiltrated lymphocytes (TILs), 
expand them in vitro, and re-infuse them back to the lymphocyte-depleted patient. 
However, it has many limitations the main one is that those expanded TILs will be supressed 
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because of the TME. The second passive IT is chimeric antigen receptor (CAR) T-cell therapy 
which consist in genetically engineered T cells whose receptor has an internal TCR-like part 
and an external antibody-like part. The main advantage of CAR T-cells is that can overcome 
immunosuppression because can recognise antigen without using MHC I.    
Finally, it is important to underscore that immunotherapy it is more effective and its effects 
last longer in immunogenic cancers also known as “hot” tumour. Those are characterized 
on the one hand by generating all the danger signals in the tumoral development site such 
as pro-inflammatory signals that activate APCs. This is the reason why “hot” tumours have 
an increased number of activated DCs (able to capture antigens), infiltrated-tumour CTL 
(able to kill cancer cell) and a high mutational load or neoantigens (peptide mutations in 
cancer cells that are not affected by central tolerance and thus differ from the human 
genome increasing the cytotoxic activity of CTL cells and NK).  On the other hand, all the 
immunosuppressive factors are diminished, for example there is an absence of checkpoint 
molecule expression or absence of inhibitory tumour metabolism. When a tumour is not 
immunogenic or is “cold”, the immune response has not initiated towards it. In those cases, 
combined therapy is optimal because firstly the “cold” tumour has to turn into a “hot” one 
and then, the immunotherapy becomes useful because it has targets attack to (18, 19). 
The variability of the immune response and the different susceptibility of tumour types 
makes IT a therapy with limited and irregular efficacy. However, due to its potential, new 
possibilities to enhance its efficacy – including the gut microbiota –  are being studied and 
they will be discussed later on in this dissertation (7). 
4.2.3. The influence of the microbiota in the immune response of the host  
One of the most important functions of the microbiota is its role in shaping both innate and 
adaptive immunity. 
As the major crosstalk between the microbiota and the immune response take place in the 
gut it is important to know its structure. The human gut is a mucosa composed by a single 
cell layer made up of intestinal epithelial cells (IECs) and intraepithelial lymphocytes. IECs 
include Paneth cells (secrete antimicrobial products such as lectin REGIIIγ and is important 
to keep the separation between the microbiota and the epithelial cells) and goblet cells 
(secrete mucus). Beneath the mucosal layer, there is the lamina propria, a connective tissue 
layer where it can be found various immune cells such as APCs, innate lymphoid cells, T cells 
and B cells, some of which are organised in Peyer’s patches. The gut-associated lymphoid 
tissue (GALT) is the largest immune component of all (20, 21). 
The microbes can trigger innate immunity by two types of signal. The first one is regarding 
microbial cell components or pathogen-associated molecular patterns (PAMPs) like 
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lipopolysaccharides (LPS). They are recognised by IECs’ and innate cells’ pattern recognition 
receptors (PRR). For instance, a study showed that three different microbiomes from 
different patient had different immunogenicity of LPS. Depending on its immunogenicity, 
patients were able to stimulate a toll-like receptor 4 (a kind of PRR) and thereby activate a 
nuclear factor involved in endotoxin tolerance.  The second type of signal to trigger innate 
immunity is regarding microbes’ metabolites. It has been seen that transcriptional 
programming of innate immune cells is influenced by metabolites. In the case of innate 
lymphoid cells by tryptophan metabolites and in the case of myeloid cells by short-chain 
fatty acids (SCFAs). The latter metabolite is involved in many activities in the gut including 
Treg development and immunoglobulin A (IgA) production by plasma cells (Figure 6). IgA 
are antibodies specialised in the intestinal protection: they block bacterial adherence to 
epithelial cells, they have effect in bacterial virulence and they can also target specific 
bacteria specially to those with colitogenic potential, among other activities (9, 20, 21).   
In addition to that, the microbiota can also activate adaptive immunity (Figure 6). PAMPs 
induce APC maturation like DCs and thus, its activation. Then DCs can travel to mesenteric 
lymph nodes (mLN), where they activate naïve T cell, and develop therefore an adaptive 
immune response (Tregs, Th1, Th2, Th17 and even CTL). It will have an enormous 
importance in the way the adaptive immunity will response. Depending on the subset of 
activated T cells that will predominate (above all Tregs or Th17), the immune system will be 
more or less stimulated being crucial to some diseases like cancer. On the one hand, Tregs 
have a paramount role in gut homeostasis since they induce commensal microbiota 
tolerance and produce immunosuppressive cytokines such as IL-10, which at the same time 
TME takes advantage of this in order to scape immunity. On the other hand, Th17 cells have 
Figure 6. The microbiota shapes innate and adaptive immune response (9). 
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a crucial role in protecting bacterial and fungal infections. By secreting IL-17 they stimulate 
IECs to form tight junction and secrete anti-microbial proteins and can recruit neutrophils 
from blood circulation to induce inflammation (9, 20). Furthermore, there are specific 
bacterial species that directly develop and differentiate the adaptive immune response. For 
example, segmented filamentous bacteria (SFB) can induce Th17 cells, whereas Bacteroides 
fragilis, certain strains of Clostridium spp. and bacteria secreting SCFA can induce Treg. In 
addition, SFB and Mucispirillum spp. can induce secretion of IgA (Figure 6) (9). Moreover, 
adaptive immunity can be activated by cytokines and interferons, secreted by innate 
immune effectors in a paracrine or endocrine manner, that give the gut a “immune system 
tone” to be rapidly present in a pathogen setting, but suppressed in a harmless setting (20).  
If the delicate ecosystem of the commensal microbiota in the gut becomes unbalanced it 
will potentially have severe defects in immunity, with an absence in mucous layer, altered 
immunoglobulin A (IgA) secretion, reduced size and functionality of Peyer’s patches, and 
draining mesenteric lymph nodes (mLNs) among other things. It has been proved in germ-
free mice (20). 
Overall, there is compelling evidence that the microbiota helps to shape the immune 
system.  
4.3. Microbiota alterations in cancer  
Despite microbiota and cancer relationship is bidirectional and multifactorial, it has been 
observed that there are cancer-associated shifts in microbiota (Table 1). For example, head 
and neck carcinomas have altered composition in oral microbiota. The same situation is 
repeated in lung carcinomas with bronchial microbiota, in colorectal carcinomas with 
intestinal microbiota or in cervical carcinomas with vaginal microbiota. These facts can be 
explained, at least, for three reasons: the first one is that cancer usually progress in an 
immunosuppressed setting which can deregulate eubiosis. Similarly, the second reason is 
that cancer also alters the host metabolism which through metabolites can also alter 
microbiota and thus, the microbiome. The third reason would be that tumour can physically 
disrupt barriers causing translocation or invasion of certain microbes into tissues that are 
not supposed to inhabit (8). 
Likewise, there are shifts in the microbiota associated to certain anticancer therapy such 
as chemotherapeutic cyclophosphamide or immunotherapeutic monoclonal antibody 
ipilimumab, which have an impact in treatment result. This association can be explained 
because these therapies take advantage of the host immune response to fight cancer and 
the microbiota plays an important role in immune system homeostasis. In the following 
section it will be discussed in more detail (8). 
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Table 1. Epidemiological associations between commensal microorganisms and cancer. ALL, acute lymphoblastic leukemia; 
CCA, cholangiocarcinoma; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; rRNA, ribosomal 
RNA; V, variable region (8). 
There are epidemiologic studies of the human microbiome and cancer that represent the 
seed towards the use of the microbiome analysis as a tool to prevent, screen, diagnose or 
even treat cancer. Even though there are factors that equally trigger carcinogenesis and 
dysbiosis and that comprehensive studies that causally link microbiota alteration with 
cancer development need to be done (2, 6). 
The influence of microbiota in breast cancer is yet to be characterised. However, in a study 
it was concluded that breast cancer patient had ten times less bacteria (in absolute 
numbers) in cancer tissue than in adjacent healthy tissue and also concluded that the 
composition of tumour tissue was high in Sphingomonas yanoikuyae. A second study 
showed that in toll-like receptor 5 (TLR5, a type of PRR) microbial signalling, mice suffered 
tumour growth whereas in absence of TLR5 signalling they had a reduced tumour 
progression, suggesting that commensal microbiota could be involved in breast cancer (22). 
Although little is known about the relationship between microbiota and breast cancer, 
there is an ongoing trial (NCT02079662) with stage III breast cancer patients initiating 
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radiotherapy that has as an object of study (as secondary outcomes) the influence of diet 
in gut and oral microbiome. Another one (NCT03358511), investigates the effects of 
probiotics in intratumoral CD8+ T cell in patients with stage I–III breast cancer indicating 
that microbiota might be relevant in breast cancers (20).  
Cervical cancer is mainly due to human papilloma virus (HPV) rather than a microbiota 
dysbiosis. However, dybiosis in vaginal microbiota is associated not only with vaginal cancer 
but also with HPV infection and, thereby, with cervical cancer. Vaginal microbiota is an 
important barrier in women against pathogens and has a rich Lactobacillus spp. composition 
that are known to have a protective function. In bacterial vaginosis, anaerobic bacteria such 
as Gardnerella, Prevotella, and Clostridiales are increased in expense of Lactobacillus spp 
(22).  
Primary liver cancer is classified as hepatocellular carcinoma (HCC) in 70-90% of the cases. 
HCC usually occurs after a previous liver damage such as hepatitis infections (by HBV and 
HCV), alcoholism or obesity, or secondary to liver diseases such as alcoholic liver disease 
(ALD) or non-alcoholic fatty liver disease (NAFLD). Many studies seem to indicate that the 
microbiota has a crucial role not only in developing those diseases but also in the 
progression of HCC. One example is ALD. Chronic consumption of alcohol provokes gram-
negative bacteria overgrowth as well as intestinal barrier disruption which lead to the 
permeability of microbes and its products and toxins to the liver. Consequently, an 
inflammatory environment is developed and can aggravate liver damage like cirrhosis. 
Moreover, it has been seen that alcoholic cirrhosis patients have increased gram-negative 
bacterial translocation in the liver and, in fact, patient that were treated with probiotics 
showed decreased gut permeability and, thus, decreased incidence of cirrhosis and HCC. 
Another example of microbiota being involved in hepatic diseases is the case NAFLD. There 
are two pathways to induce NAFLD. The first one is through obesity, that also increases gut 
permeability and led gram-negative bacterial products such as LPS to translocate to the 
liver. As a result, TLR4 and TLR9 signalling pathways can develop NAFLD and also tumour 
formation. The second one is because of gram-positive bacteria that produce secondary bile 
acid such as deoxycholic acid (DCA) which is known to produce DNA damage and thus, 
cancer. In fact, HCC progression in mice could be stopped when treated with vancomycin, 
a specific gram-positive antibiotic. All in all, in the future HCC prevention and treatment will 
greatly benefit from microbial modulation therapy since the correlation between 
detrimental dysbiosis and the disease itself is clear (22).  
Microbiota alteration in colorectal cancer (CRC) has been widely studied because it was the 
first cancer to be related to detrimental gut dysbiosis. Perhaps because the gut microbiota 
shares space with colon and seemed to have more causative impact on CRC than in other 
extraintestinal cancers. Likewise, differences in microbiota composition in a CRC have been 
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described in many scenarios: between healthy subjects and CRC patients, between a same 
patient’s tumour tissue and healthy adjacent tissue, and between different stages of one 
same tumour: from adenoma to adenocarcinoma. The main intestinal changes that many 
studies agree in CRC patients are increased abundance of Fusobacteria, Alistipes, 
Porphyromonadaceae, Coriobacteridae, Staphylococcaceae, Akkermansia and 
Methanobacteriales and decreased abundance of Bifidobacterium, Lactobacillus, 
Ruminococcus, Faecalibacterium, Roseburia and Treponema. Although it is assumed that 
microbiota and cancer communication occur in a bidirectional fashion, there are strong 
preclinical models, at least for CRC, that evidence the causal effects of detrimental dysbiosis 
in CRC. In a study that compared the gut microbial composition of a colon tumorigenesis 
model mice (in a pre-neoplastic stage) and a wild type one, born at the same time, it could 
be seen that the first one showed dysbiosis. It is believed that the mechanisms by which the 
gut microbiota causes CRC is by inducing host immune response and certainly, there are 
four ways known to contribute to tumorigenesis. The first one is through proinflammatory 
cytokine production. The second one, by pattern recognition receptors (PRR) that, when 
are induced by certain microbial pathogen-associated molecular patterns (PAMPs), they can 
control epithelial growth and promote eubiosis. The third one is by inflammasomes, 
multiprotein complexes that, when activated, they secrete inflammatory mediators that 
similarly to PRR, they avoid tumorigenesis by controlling epithelial growth, promoting 
eubiosis and in addition, they can supress metastatic growth. The fourth one is by the 
expression of autophagy genes that promote tumorigenesis and decrease CD8+ T cells. 
Moreover, it is known that enterotoxigenic Bacteroides fragilis (ETBF), E. coli, and 
Fusobacterium nucleatum are specially involved in CRC by producing toxins and genotoxins. 
To finish, using altered microbiota as a non-invasive diagnostic tool seems to be feasible in 
CRC patient, although there are still many challenges such as reproducibility and 




4.4. The influence of microbiota in the efficacy and toxicity of 
certain anti-cancer drugs.  
As it was discussed before in this 
dissertation, there is mounting 
evidences of the role of the gut 
microbiota in modulating host 
immunity and thus having an 
immunotherapeutic effect against 
some diseases such as cancer. For 
instance, the translocation of bacterial 
products like LPS from the intestinal 
lumen to the secondary lymphoid 
organs enhances the efficacy of 
tumour-specific T cells (10). Therefore, 
it is reasonable to think that the 
microbiome could influence efficacy 
and toxicity to various forms of cancer 
therapy especially because the 
microbiota is involved in the 
biotransformation of some anticancer drugs (Figure 7). Results obtained in mice with anti-
cancer treatments such as cyclophosphamide, platinum salts or monoclonal antibodies 
(mAbs), like CTLA-4 or PD-1/PD-L1, showed a reduced therapeutic effect in germ-free mice 
and broad-spectrum treated mice, suggesting once more the importance of the microbiota 
in anti-cancer drugs (10). In the following section it will be discussed the fine mechanisms 
by which the microbiome modulates some anti-neoplastic therapy responses and the 
different outcomes of each treatment modality.    
4.4.1. Irinotecan 
Irinotecan is an antineoplastic agent quite used in metastatic colorectal cancer. It inhibits 
the topoisomerase I. In order to understand how the microbiota in the gut modulates its 
toxicity it is important to first know about its pharmacodynamics. Irinotecan is a prodrug 
that it is transformed into its active form (SN-38) in the liver and small intestine tissue 
through carboxylesterase. Afterwards it is processed in the liver by host UDP-
glucuronosyltransferases to form inactive SN-38G derivative, which is later excreted via 
biliary ducts into the GI tract. Because of bacterial β-glucuronidases –present in the gut– 
SN-38G can turn into its cytotoxic SN-38 form and cause severe diarrhoea intestinal 
inflammation in many patients that leads to dose reduction or change of treatment.  
Figure 7. Healthy microbiota is involved in the biotransformation 
of anticancer therapeutic drugs which can result to be effective and 
inhibit cancer (can also act synergically with the immune system) 




In order to avoid this major drawback a selective bacterial β-glucuronidase inhibitors must 
be developed. So far, Kampo medicine and D-saccharic acid 1,4-lactone that slightly inhibit 
β-glucuronidases have shown to alleviate diarrhoea. Another option would be the usage of 
antibiotics or probiotics in order to change the proportion of bacterial species expressing β-
glucuronidase that have been seen to increase after irinotecan chemotherapy. Concretely, 
in some members of Clostridium, Enterobacteriaceae and Bacteroidetes (ie. B. fragilis). In 
experimental animal, antibiotics effectively treat intestinal inflammation induced by 
irinotecan therapy, while it modestly decreased irinotecan induced diarrhoea. As the 
intestinal toxicity of irinotecan in humans is severe and dose limiting, there is much interest 
in the development of an effective solution to reduce toxicity (7,13). 
4.4.2. Cyclophosphamide  
Cyclophosphamide (CTX) is a prodrug used against multiple hematologic and solid 
malignancies that once activated acts as an immunostimulatory and cytotoxic alkylating 
agent by inducing immunogenic cancer cell death, subverting immunosuppressive T cells 
and promoting Th1 and Th17 cells. In a study conducted by Viaud et al. 2013 (23) it was 
demonstrated that CTX efficacy depended on commensal bacteria, notably on Gram-
positive bacterial species Lactobacillus johnsonii and Enterococcus hirae. Administration of 
CTX in mice led to the disruption of small intestinal barrier function, enabling the 
translocation of these intestinal bacteria into mesenteric lymph nodes and spleen. There, 
they stimulated the generation of a specific subset of "pathogenic" (p)Th17 cells and 
memory Th1 immune responses, which are the key of the success of this chemotherapy 
(Figure 8). In order to prove that the gut microbiota was crucial in driving the conversion of 
naïve CD4 towards Th1 and pTh17 subsets, CTX was administered to germ-free (GF) and 
specific-pathogen-free (SPF) tumour-bearers’ mice. The results showed that in SPF mice the 
number of lactobacilli and segmented filamentous bacteria (SFB) measured in the small 
intestine mucosa correlated with the Th1 and Th17 polarization, whereas in GF mice a 
reduction in pTh17 cells and thereby a resistance to CTX was observed. However, transfer 
of ex-vivo propagated pTh17 cells (but not Th17 cells) restored the therapeutic effect of CTX 
in tumour-bearing mice that had been treated with vancomycin, an antibiotic that target 
Gram-positive bacteria (23). All in all, it can be concluded that CTX anticancer immune 
response –one of the most important mechanisms of CTX– is due to mainly pTh17 cells that 
strictly depend on certain species of Gram-positive bacteria found in the gut microbiota. 
4.4.3. Immunotherapy: Anti-PD-1/PD-L1 and CTLA4 monoclonal antibodies  
Immunotherapy has been one of the most promising and successful achievements in cancer 
care in the last decade. Especially immune checkpoint blockers (ICB) that have improved 
the overall survival in many cancer patients. Monoclonal antibodies (mAbs) that block CTLA-
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4 and PD-1/PD-L1 checkpoints occur to be the ones with most clinical success.  Moreover, 
due to its different mechanism of action, anti-CTLA-4 and anti-PD1/PD-L1 antibodies 
combination have shown great clinical response in some melanomas in expense of slightly 
increased toxicity (18). However, their efficacy and toxicity are influenced and regulated by 
the gut microbiota.  
Regarding anti-CTLA-4 mAbs efficacy it has been observed that tumour-bearer mice breed 
in germ-free condition or treated with antibiotics show a decreased therapeutic efficacy: 
suppressed effector CD4+ T cells and reduced tumour-infiltrating lymphocytes (TIL) and Th1 
cells. However, DCs exposed to Bacteroides fragilis, Bacteroides thetaiotaomicron and 
Burkholderia cepacia have been associated with anticancer properties because 
immunostimulatory effects produced by CTLA-4 blockade require IL-12 in order to induce a 
Th1 and CTL immune response. Likewise, those exposed DCs induce IL-12 and, thereby, 
restore CTLA-4 efficacy, which correlates with induced Th1 immune responses in tumour-
draining lymph nodes and DC maturation in tumour beds. Moreover, memory Th1 anti-
tumoral response is observed against B. fragilis and B. thetaiotaomicron. Regarding anti-
CTLA-4 mAbs toxicity, it has been noticed that after its administration, immune related 
adverse events such as colitis take place and often dictates a treatment suspension. It has 
been observed that this unfortunate event is more frequent in SPF mice than GF mice, 
Figure 8. The influence of microbiota in drug efficacy and toxicity (2). 
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suggesting that commensal bacteria are involved in anti-CTLA-4 mAbs dysregulation of the 
equilibrium among IECs, and gut microbiota at the intestinal barrier. Nonetheless, it has 
been tested that B. fragilis and B. cepacia –that also restore CTLA-4 mAbs efficacy– not only 
do not cause colitis but instead provide protection to anti-CTLA-4-induced intestinal lesions 
by promoting Treg cells in lamina propria. For all those reasons, colonization of the gut by 
B. fragilis and B. cepacia could be part of anti-CTLA-4 treatment not only to increase its 
efficacy but also to reduce its toxicity (Figure 8) (24,25). 
Regarding anti-PD-L1 mAbs there is a study conducted by Sivan et al. (2015) (26) that 
demonstrated that Bifidobacterium species promoted antitumor immunity and facilitates 
anti-PD-L1 efficacy in mice. The study compared subcutaneous melanoma growth in 
genetically similar mice coming from different mouse facilities, Jackson Laboratory (JAX) 
and Taconic Farms (TAC) which differ in their commensal microbes. It was seen that tumour-
specific T cell responses and intratumoral CD8+ T cell were significantly higher in JAX mice, 
whereas tumours were growing more aggressively in TAC mice. Later, JAX mice were forced 
feeding with TAC faecal suspension and vice versa before tumour implantation, in order to 
test the role of commensal bacteria in regulating antitumor immunity. TAC mice fed with 
JAX faecal suspension delayed tumour growth and enhanced induction and infiltration of 
tumour specific CD8+ T cells whilst the reciprocal faecal transfer (from TAC mice into JAX 
mice) did not show any improvement in neither tumour growth rate nor antitumor T cell 
responses proving JAX-dominant effects. Comparative analysis showed that 257 taxa were 
of significantly different relative abundance in JAX mice than in TAC mice, but 
Bifidobacterium species was the only one that demonstrated to be associated with 
antitumor T cell responses. Finally, it was seen that JAX faecal material alone significantly 
decreased tumour growth (by amplifying tumour-specific T cell responses and infiltration of 
antigen-specific T cells into the tumour) as much as systemic PD-L1 mAb. Likewise, PD-L1 
therapy alone was significantly more efficacious in JAX mice than in TAC mice. Similar to 
CTLA-4 microbiota-mediated efficacy, DCs exposed to Bifidobacterium result to be 
associated to anticancer properties because they induce systemic IL-12 which lead to Th1 
immune responses in tumour-draining lymph nodes, DC maturation in tumour beds and 
tumour-specific CD8+ T cell improvement of its effector function (Figure 8) (26). 
When studies are conducted in patients rather than in mice results tend to differ. It is true 
that most of them undoubtedly claim the role of the gut microbiota in shaping responses 
to immunotherapy. Nevertheless, it becomes complicated to determine which bacterial 
taxa are associated with response or toxicity (24). For example, to test anti-CTLA-4 toxicity, 
one study concluded that anti-CTLA-4-treated melanoma patients who were colitis-free had 
an enrichment of Bacteroidetes (27), whereas another one concluded that patients with a 
higher abundance of Faecalibacterium prausnitzii and other related Firmicutes and low 
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abundance of Bacteroidetes had a higher risk of colitis on anti-CTLA-4 therapy (28).  Another 
example, to study anti-PD-1/PD-L1 efficacy revealed differences between researches. One 
of them resolved that Akkermansia and Alistipes species were enriched in responding 
patients (29), whereas another one concluded that responders to anti-PD-1 mAbs had a 
higher relative abundance of Clostridiales, Ruminococcaceae and Faecalibacterium and 
non-responders had a higher relative abundance of Bacteroidales (30). Moreover, a third 
study confirmed that patients who responded to anti-PD-1 therapy had enrichment of 
Bifidobacterium longum, Collinsella aerofaciens, and Enterococcus faecium (31).  
All these variances can be attributed to different techniques used to analyse samples or to 
different reference databases which advocate standardized approaches for microbiome 
analysis. However, in the microbiota analysis there are some factors such as diet and 
lifestyle that have a deeply geographical influence and it is very difficult to manage. 
4.5. Therapeutic benefits of bacteria  
The microbiome is as important as our own DNA. Constant and dynamic communication 
between the microbiota and the host occurs through metabolic and immune interactions. 
Therefore, altered gut microbiota is involved in diverse aspects of disease which offers a 
wide range of opportunities for intervention. From preventing diseases to developing new 
therapeutics or optimising health (Figure 9) (32).   
The microbiota – comparable to hormonal communication – exchanges chemical 
information with multiple host tissue compartments through metabolic axis and in a 
multidirectional fashion. Examples of such axis are bile acid production, gut permeability, 
brain signalling or enteric nervous system modulation. New therapeutic opportunities could 
arise from targeting some of these metabolic pathways. In fact, pharmacometabolomic is a 
field that studies pre-interventional metabolic signatures to predict post-interventional 
outcomes of drug treatment and gives answers to interindividual variations of certain drugs 
responses that cannot be explained by pharmacogenomics (32). 
Microbiota modulation using prebiotics, probiotics or antibiotics have been used in order 
to prevent diseases or optimise health (dysbiosis is the source or the cause of several 
diseases such as diabetes, cancer or obesity), although further research have to be done in 
order to understand the cause-effect relationships of epidemiological associations. 
Likewise, microbiome modification is a newer and yet-to-be-implemented therapeutic 
opportunity that revolves around “druggable microbial genome”, a concept where 
microbial genes involved in host-microbe metabolic and signalling pathways can be 
specifically targeted in order to control microbial activities to particular host pathways.  
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Engineering the microbiota to correct abnormalities in metabolic or signalling pathways 
involved in disease is another way to improve human health through microbiome 
modulation (32). Many examples show the major impact of gut microbiome on host 
metabolism. Polyamines (like vitamin B6) elicits anticancer immune response in 
chemotherapy settings and reduce toxicity of CTLA-4 mAbs.  Short-chain fatty acids provide 
an energy to colon microbes but are also pharmacologically active, inducing angiogenesis in 
the gut mucosa or desaminotyrosine (DAT) that protect from influenza virus–mediated lung 
immunopathology through type I IFN signalling (10).  
4.5.1. Oncomicrobiotics and the study of the microbiome 
It is undeniable the crosstalk between dysbiosis and oncogenesis, and between the gut 
microbiota and anticancer therapy both in a bidirectional way. In a cancer setting, due to 
anticancer therapy or because of oncogenesis, it is common to find the gut in a dysbiotic 
state. Dysbiosis can be detrimental – when for example, limits therapeutic effects or 
increases toxicity – or beneficial – when enhance clinical activity. Hence, manipulation of 
the gut microbiota, as an adjuvant in anticancer therapy to improve therapeutic index, 
seems to be reasonable (10). 
Figure 9.  Therapeutic modulation of the gut microbiota. A general view (32). 
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Oncomicrobiotics is a new concept that can be described as a select “cocktail of bacteria 
and/or bacterial products” aimed to recuperate the natural microbiota or mimic its many 
beneficial effects that in the case of cancer treatment, it is focused in promoting beneficial 
immune response. Despite oncomicrobiotics still does not exist, its formulation will 
supposedly contain clinical products such as probiotics (living microorganisms that provide 
health to the host), prebiotics (compounds that stimulate growth and activity of bacteria in 
the gut) and antibiotics. It might be required as an individual or combined therapy. 
Nonetheless, before choosing the right bacteria or bacterial products to achieve the 
adjunctive oncomicrobiotics, cancer-associated intestinal dysbiosis must be described (24). 
So far, in order to study the gut microbiome and thus all the gut microbiome-related 
diseases such as cancer, metagenomics – which consists of sampling the genome sequences 
of a community of organisms inhabiting in a common environment – has been used. This 
revolutionary method spotlighted the understanding of the relations among the human 
microbiome, health and diseases. However, metagenomics presented some limitations 
related to DNA extraction methods and amplification steps and big-data computerized (10). 
Fortunately, culturomics – the rebirth of culture – was developed in 2008 and meant a 
breakthrough in microbiology. Culturomics is a high-throughput method that multiplies 
culture conditions in order to detect higher bacterial diversity and it can cultivate all 
microbes living in human mucosae. It combines diversified culture media and rapid 
identification of bacterial colonies using matrix-assisted laser desorption/ionization–time-
of-flight (MALDI-TOF) mass spectrometry alone or combined with 16S rRNA sequencing. 
Compared to metagenomics, which has generated several sequences that have not been 
assigned to a known microorganism, culturomics allows the culture of many 
microorganisms including those previously not assigned to a sequence. Moreover, it 
enables to correlate specific cancer parameters with a concrete microbial species or 
subspecies rather than with a phyla or genera, that often can include oncogenic and onco-
suppressive species and subspecies at the same time. All in all, it is a solid strategy to resolve 
the gaps of metagenomics. In fact, the number of species isolated from the human gut have 
been doubled by culturomics. Because of that, nowadays it is possible to develop such a 
new and ambitious field in therapeutic research such as oncomicrobiotics and in the future 
it will be possible to discover more diagnosis and therapeutic tools for cancer (33).  
4.5.2. Possible strategies to improve gut microbiome in cancer treatment  
Cancer is the most challenging disease that humanity faces in this century because in many 
cases treatment is not efficient and most times early diagnosis is the best ‘cure’. 
Consequently, it is understandable that cancer research not only puts an effort in current 
anti-cancer therapies but also in different strategies that are indirectly related to cancer 





Figure 10. Interventions on the microbiota in cancer (8). 
Prebiotics are dietary or chemical entities that enhance colonization and expansion of host 
microorganisms as well as those naturally ingested over life. As they are believed to 
promote health such as anticancer properties they have been thought as a strategy against 
cancer. Non-digestible polysaccharides such as dietary fibre or inulin are examples of 
prebiotics, that can be metabolised by bacteria. These bacterial metabolites such as shot-
chain fatty acids (SCFAs) have therapeutic interest rather than prebiotics themselves. 
Acetate, butyrate and propionate are SCFAs produced in colon by Clostridium clusters IV 
and XIVa. Acetate can be involved in several cancer types’ growth. Opposite to acetate, 
propionate and butyrate have an onco-suppressive effect by inhibiting histone deacetylases 
and by differentiating and accumulating Treg cells which mediates anti-inflammatory 
effects and reduce colorectal carcinogenesis risk (8). Prebiotics are linked with diet which if 
changed intensively alter gut microbiota. In a study, where healthy human subjects reduced 
dietary fibre intake, showed reduce in abundance of Faecalibacterium prausnitzii which 
promotes immunity. Similarly, in another study with inulin supplementation, both 
Faecalibacterium and Bifidobacterium species, that enhance host immunity where 
significantly incremented. Besides, a different study concluded that animal fat free diet 
decreased detrimental Bacteroidales. Finally, antitumor effects of cytotoxic cancer drugs 
like anthracyclines where seen to be increased when co-administrated with prebiotics in 
mice. The main advantage of prebiotics and diet as a strategy to improve gut microbiota is 
that are viable in terms of safety profile and cost (20). 
The use of probiotics - live microorganisms with health benefits - is a strategy to improve 
dysbiosis and thus, all its beneficial effects. There are many examples of probiotics that are 
thought to enhance the immune system and its anticancer activities in very different 
context (Figure 11). However, some of them have limited clinical evidence of effectivity. 
Lactobacillus spp. are known to potentiate the immune system by different mechanisms 
such as NK cell activation, DCs cell maturation or ferrochrome peptide release. An example 
of the latter is L. casei which induces apoptosis of tumorigenic cells through JNK pathway. 
Moreover, Prohep, a mixture of L. rhamnosus and E. coli, showed a potent anti-angiogenic 
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and anti-inflammatory effect in mice with hepatocellular carcinoma. The anti-inflammatory 
effect was achieved by shifting gut microbial composition towards certain species that 
reduced pro-inflammatory Th17 cell while differentiate to Treg cells. Alistipes shahii may 
improve innate immune cell response to immunotherapy. In a study with germ-free mice, 
those that were inoculated with A. shahii showed increased number of infiltrating innate 
immune cells against colorectal cancer. Bacteroides fragilis has a dual role in cancer. The 
enterotoxigenic strains elicit inflammatory Th17 cells and accelerate carcinogenesis 
whereas the non-enterotoxins-producing strains have shown great results in an anti-CTLA4 
setting; they induce memory T cells and promote matured intra-tumoral dendritic cells (DC). 
A study demonstrated it with GF mice that received anti-CTLA4 treatment which could not 
reduce their subcutaneous sarcoma growth. However, the situation could be reverted by 
inoculating B. fragilis and CD4+ T cell previously primed by B. fragilis-pulsed DC. Those 
inoculated mice showed more mature DC inside the tumour than control mice and the 
reason seems to be the immunogenic polysaccharide A of B. fragilis’ cell wall. Similarly, 
Burkholderia cepacia also mature intra-tumoral DC in vitro. B. fragilis and B. cepacia 
combined have a synergic anticancer effect in CTLA-4 blockade context. Barnesiella 
intestinihominis abundance in colon is increased after cyclophosphamide (CTX) treatment 
in mice and it is related to more functional CD4+, CD8+ or γδ T cells in spleen and tumour 
bed. Additionally, combination of CTX with B. intestinihominis reduces cancer growth in 
mice. In CTX context in mice, Enterococcus hirae induces Th17 and Th1 CD4+ T cells, 
stimulates CD8+ T cells and reduce Treg cell because they translocate to lymphoid organs 
from the small intestine lumen. Colonization of both B. intestinihominis and E. hirae is 
inhibited by NOD2-receptor (a type of patter recognition receptor) and thereby their 
immunostimulatory effects are more pronounced in NOD2-deficient mice. Synergy 
between B. intestinihominis and E. hirae is still to be determined. Finally, Bifidobacterium 
breve and B. longum stimulated dendritic cell maturation and thus, enhanced tumour 
specific CTLs priming. Compared to Bifidobacterium-free mice, those that contained B. 
breve and B. longum had better outcomes to immunotherapy because CTLs function was 
improved and could easily infiltrated into tumour (8). One of the main advantages of 
probiotics is that some species show a clear improvement of the immune system to fight 
against cancer (especially anti-tumour T cell response) and seems more appropriate to 
boost the gut microbiota than prebiotics. However, more efficacy and safety studies need 
to be done because on the one hand there are studies that suggest that probiotics with 
more than one species have larger efficacy than probiotics with a single species. On the 
other hand, it has been seen that probiotics in some cases can confer tumorigenesis instead 
of protection against cancer, so it is important to take into account each situation (2, 20). 
Finally, a future major drawback with probiotics might be that, if they become 
therapeutically indicated to treat cancer, their current commercial regulation status as 
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dietary supplement will have to change to drug with all the strict regulation and quality 
certificates that they require (10).  
Since it is known the existence of unfavourable bacteria in the gut, the use of antibiotics 
seems a feasible strategy to shape gut microbiota to improve cancer treatment. However, 
for a long time, some studies have associated through epidemiological studies that 
continuous exposure to broad-spectrum antibiotics in life correlates with a higher 
predisposition to develop cancer (not only colorectal but also lung, prostate and bladder 
cancer) linking microbiota with carcinogenesis (1, 11). Moreover, the problem with 
antibiotics is also their lack of specificity which could undermine favourable microbiota 
(although in the food industry they use bacteriophages as highly selective method to 
eliminate unwanted bacteria) (10). One example to display antibiotic’s tricky efficacy is 
vancomycin. In an anti-CTLA4 treatment vancomycin is used to eliminate Gram-positive 
bacteria such as Clostridiales in order to Gram-negative Bacteroidales to expand and 
therefore induce Th1 cells immune response which favour CTLA-4 blockade antitumor 
efficacy. Nevertheless, vancomycin reduces its immunogenic response and thus its 
anticancerogenic effect in a CTX setting. In conclusion. it could be stated that antibiotics 
Figure 11. Potential immune mechanisms that explain the anticancer effects of probiotics (8). 
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therapy alone to improve cancer treatment seems risky, however, as adjunctive 
oncomicrobiotics (combined with pre- and/or probiotics) could be a reasonable strategy to 
eliminate detrimental bacteria (8).  
Faecal microbial transplantation (FMT) consist of exchanging gut microbiota (especially 
from the lower gastro-intestinal tract) from healthy donors to patient with detrimental 
dysbiosis. Nowadays, FMT is a strategy used to treat Clostridium difficile infection resistant 
to conventional therapy with a high rate of positive response (80-90%) and a promising one 
to irritable bowel syndrome. The growing popularity and the earliest advances of this 
technique (stool from heathy donors now is packed into pills) make FMT appealing to 
modulate the gut microbiota in order to improve cancer treatment although this idea is still 
on its beginning. FMT from healthy donors to mice have shown incredible results to many 
anticancer therapies, however, when FMT from colorectal patients was practiced into germ-
free mice dysplasia and polyp formation arisen. FMT needs further research because 
commensal composition not only modulates the immune response but also plays an 
important role in chronic diseases such as depression or obesity that could be accidentally 
transferred. Nonetheless, it is worthwhile to keep trying to implement this strategy because 
long-term reset of the microbiota can be achieved (2, 8, 10, 20).  
Even though these strategies are the most relevant ones, there are others unconventional 
and yet-to-have scientific evidence strategies that in the future they might be used in cancer 
treatment. For example, the use of bacterial toxins, pathogen-associated molecular 
patterns (PAMS), bacterial metabolites (8) or even though the own bacteria as a shuttle 













The most relevant ideas of this dissertation can be summarised as follows.  
Firstly, the microbiota has an impact in carcinogenesis as well as carcinogenesis can cause 
or worsen dysbiosis. Some microbes can directly cause cancer as they have intrinsic 
oncogenic effects or because they alter carcinogenic metabolites. Others induce 
carcinogenesis indirectly, by destabilising immunosurveillance via immunosuppressive or 
proinflammatory effects. At the same time, tumours can alter microbiota composition 
through its tumour microenvironment (TME) which is rich in proinflammatory cytokines and 
reactive immune cells. Sometimes that leads to cancer-associated shifts of microbiota like 
in colorectal cancer, hepatocellular carcinoma or breast cancer, which have been 
epidemiologically associated to some bacterial species.  
Secondly, the immune system has a cancer-immunity cycle capable to eliminate cancer cells 
and keep homeostasis, however, tumours can develop mechanisms to scape this cycle such 
as loss of antigenicity or immunogenicity. Nonetheless, the microbiota can activate the 
innate and above all the adaptive immune system, which in turn, depending on the bacterial 
species can trigger different subset of T cells which will determine the cancer outcome. 
Improved outcomes (reduction of cancer growth, less progression, etc.) will be related to 
beneficial dysbiosis, whereas worsened outcomes (tumour growth, increased cytokines, 
etc.) will be related to detrimental dysbiosis. 
Thirdly, the efficacy and toxicity of certain anticancer drugs (chemotherapy, 
immunotherapy or even radiotherapy) depend on the microbiota and in some cases on 
particular species. This fact opens a great new opportunity to enhance efficacy or avoid 
toxicity in cancer patient by previously modulating the microbiota before anticancer 
treatment.  
Fourthly and lastly, understanding the role of the microbiota in the human body in order to 
modulate it to human health profit is one of the challenges of the 21st century medicine. 
There are many medicine fields that could greatly benefit from it and oncology is one of 
them. The mechanisms by which the microbiota causes carcinogenesis need to be known. 
In this way, it is made sure that current strategies to modify the gut microbiota to prevent 
or to help curing cancer are appropriate. Likewise, potent techniques like culturomics are 
required to truly know the significance of the microbiota and all the benefits resulting from 
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